1. Sanofi. JEVTANA® (cabazitaxel) Injection, Summary of Product Characteristics. Paris, France, 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002018/human_med_001428.jsp&mid=WC0b01ac058001d124 . Accessed 20 December 2013
2. Sanofi U.S. LLC. JEVTANA® (cabazitaxel) Injection, Prescribing Information. Bridgewater, NJ, USA, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf . Accessed 20 December 2013
3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
4. Semiond D, Sidhu SS, Bissery M-C, Vrignaud P (2013) Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemother Pharmacol 72:515–528
5. FDA Guidance for Industry. Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf . Accessed 20 December 2013